What do Cochrane systematic reviews say about interventions for autism spectrum disorders?

What do Cochrane systematic reviews say about interventions for autism spectrum disorders?

Author Lyra, Larissa Autor UNIFESP Google Scholar
Rizzo, Luiz Eduardo Autor UNIFESP Google Scholar
Sunahara, Camila Sa Autor UNIFESP Google Scholar
Pachito, Daniela Vianna Autor UNIFESP Google Scholar
Cruz Latorraca, Carolina de Oliveira Autor UNIFESP Google Scholar
Cabrera Martimbianco, Ana Luiza Google Scholar
Riera, Rachel Autor UNIFESP Google Scholar
Abstract CONTEXT AND OBJECTIVE: Autism spectrum disorders (ASDs) include autistic disorder, Asperger's disorder and pervasive developmental disorder. The manifestations of ASDs can have an important impact on learning and social functioning that may persist during adulthood. The aim here was to summarize the evidence from Cochrane systematic reviews on interventions for ASDs. DESIGN AND SETTING: Review of systematic reviews, conducted within the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de Sao Paulo. METHODS: We included and summarized the results from Cochrane systematic reviews on interventions for ASDs. RESULTS: Seventeen reviews were included. These found weak evidence of benefits from acupuncture, gluten and casein-free diets, early intensive behavioral interventions, music therapy, parent-mediated early interventions, social skill groups, Theory of Mind cognitive model, aripiprazole, risperidone, tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI)

this last only for adults. No benefits were found for sound therapies, chelating agents, hyperbaric oxygen therapy, omega-3, secretin, vitamin B6/magnesium and SSRI for children. CONCLUSION: Acupuncture, gluten and casein-free diets, early intensive behavioral interventions, music therapy, parent-mediated early interventions, social skill groups and the Theory of Mind cognitive model seem to have benefits for patients with autism spectrum disorders (very low to low-quality evidence). Aripiprazole, risperidone, tricyclic antidepressants and SSRI (this last only for adults) also showed some benefits, although associated with higher risk of adverse events. Experimental studies to confirm a link between probable therapies and the disease, and then high-quality long-term clinical trials, are needed.
Keywords Autism spectrum disorder
Therapeutics
Review [Publication type]
Evidence-based practice
Evidence-based medicine
xmlui.dri2xhtml.METS-1.0.item-coverage Sao Paulo
Language English
Date 2017
Published in Sao Paulo Medical Journal. Sao Paulo, v. 135, n. 2, p. 192-201, 2017.
ISSN 1516-3180 (Sherpa/Romeo, impact factor)
Publisher Associacao Paulista Medicina
Extent 192-201
Origin http://dx.doi.org/10.1590/1516-3180.2017.0058200317
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000402009700017
URI https://repositorio.unifesp.br/handle/11600/54964

Show full item record




File

Name: WOS000402009700017.pdf
Size: 147.5Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account